AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02091193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Placebo (Supplement B)
Study NCT04006067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: changing surgical gloves
Description: All the surgical team including surgeons, surgical assists and scrub technicians replaced their outer surgical gloves with a new pair of sterile gloves just prior to abdominal closure.
Study NCT01844427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.
Study NCT01844427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03713827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tooth restoration
Description: restoration of non carious cervical lesions with two different restorative materials
Study NCT06216106 — intervention group
Intervention type: PROCEDURE
Intervention: Prepectoral breast reconstruction with polyurethane implants
Description: Breast reconstruction in the prepectoral plane without elevate the pectoralis major muscle. We choose this type of reconstruction only in patients with mastectomy flap thickness of plus then 0.5 cm. We usally use silicone implants covered by an external layer of polyurethane so not to put directly in contact the silicone with the subcutaneus tissue.
Study NCT02558283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLIFT® with Lidocaine
Description: JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
Study NCT02558283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane®
Description: Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
Study NCT02705222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D&C
Description: Cervical dilatation and fractional endometrial curettage will be done in operation theatre and the curetting will be sent for histopathological examination
Study NCT02705222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopy
Description: Hysteroscopy will be done in operation theatre and hysteroscopic-guided curettings will also be taken and sent for histopathological examination
Study NCT01570205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG-102
Description: single intravenous infusion
Study NCT01570205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XG-102
Description: single intravenous infusion
Study NCT01529450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225
Description: 800-mg (4 200-mg capsules/day) capsule
Study NCT03630016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse oximetry with Owlet BabySat v1.0 sensor
Description: A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors
Study NCT03630016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pulse oximetry with Owlet BabySat v1.0 sensor
Description: A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors
Study NCT03013959 — intervention group
Intervention type: DRUG
Intervention: Pranoprofen
Description: it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
Study NCT03797690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous needle aponeurotomy
Description: It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure
Study NCT03797690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery with limited aponeurectomy
Description: It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy)
Study NCT03512119 — intervention group
Intervention type: DRUG
Intervention: Lumacaftor-Ivacaftor treatment
Description: Lumacaftor-Ivacaftor treatment during one year
Study NCT03422016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: electroretinogram (ERG)
Description: an ERG is a measure of the eyes response to a flash of light
Study NCT01313468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 x 4 minute interval
Description: 1 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
Study NCT01313468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 x 4 minutes Intervals
Description: 4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
Study NCT01313468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate continuous Training
Description: 47 minutes of Moderate continuous Training
Study NCT02283983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cooling helmet
Study NCT01523990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349
Description: Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
Study NCT02502279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Engström Datex-Ohmeda ICU Ventilator
Description: patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation.
Study NCT02502279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative CPAP mask
Description: patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation and a CPAP mask will be applied immediately postoperative.
Study NCT01387074 — intervention group
Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
Study NCT02849184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
Study NCT03155997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Adjuvant Endocrine Therapy
Description: Administered according to label instructions.
Study NCT03155997 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard Adjuvant Endocrine Therapy
Description: Administered according to label instructions.
Study NCT04694846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Given NRT via trans-dermal patch, gum, nasal spray, inhaler or lozenges
Study NCT04694846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride Controlled-release
Description: Given PO
Study NCT04694846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Given PO
Study NCT02849184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily before bedtime.
Study NCT03809156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat Oral Product
Description: Dual therapy of Riociguat and Ambrisentan at initiation of treatment.
Study NCT02231489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Tablet
Description: Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.
Study NCT02231489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Capsule
Description: Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.
Study NCT02231489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61818549
Description: Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.
Study NCT03058302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CETA (Common Elements Treatment Approach)
Description: The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
Study NCT01155791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV 75 mg/m2
Study NCT01155791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biosyn
Description: IV dosage varies
Study NCT01155791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5mg, orally
Study NCT03200795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound exercise
Description: Each participant will undergo 3 sessions a week for 8 weeks with each session lasting 20 minutes. Bouncing frequency will be determined by signals from an metronom and will be set at between 90 and 120 bounces per minute. Heart rate training zone will be maintained, during the exercise, at moderate intensity of 40-60% and will be calculated using the Karvonen formula (\[Heart rate reserve x training percentage\] + resting heart rate)(Nuhu \& Maharaj, 2017).~The exercise will involve bouncing on the center portion of the mini trampoline (Portable 2013 Model Half-Fold Cellerciser with feet slightly apart and knees in full extension. Each foot strike equaled one step or bounce with step height, this will be defined as the distance between the foot at maximum height of jump and the bed of the center of the trampoline ranging between 10 and 15 cm (Nuhu \& Maharaj, 2017).
Study NCT03200795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training exercise
Description: Participants will be instructed to exhale while lifting a weight and inhale while lowering it, to minimize blood pressure excursions, and to rest for 2 to 3 minutes between sets. Participants will perform 1 set per resistance exercise three time weekly for the first 2 weeks and 4 sets of each resistance exercise three time weekly during weeks 3 and 4. Resistance will be increase by 5 to 10 kg when the participant could perform more than 15 repetitions while maintaining proper form.~All aerobic activities of the circuit training will be performed on a cycle ergometer or treadmill. Participants are free to vary the machine used from one visit to the next. Exercise intensity will be standardized by using heart rate monitors (Polar Electro Oy) that will display the participant's heart rate and emitted a warning signal when the heart rate was outside the prescribed training zone, thus guiding the participant in adjusting the workload up or down to achieve the desired intensity.
Study NCT03457636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Anhydrous 40 MG
Description: One Oracea Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals
Study NCT03457636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/Benzoyl Peroxide Gel 0.3-2.5%
Description: Epiduo Forte should be applied in a thin layer to affected areas of the face and/or trunk once daily after washing, with care taken to avoid the eyes, lips, and mucous membranes
Study NCT00572728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT
Description: Undergo 18F-FLT PET/CT
Study NCT00572728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FLT
Description: Undergo 18F-FLT PET/CT
Study NCT00572728 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET
Description: Undergo 18F-FLT PET/CT
Study NCT02143141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duramorph
Description: duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
Study NCT02143141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
Study NCT02732184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-ArgI-PEG modified human arginase I
Study NCT01963936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supreme LMA
Study NCT01963936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facial mask
Study NCT01553721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: udenafil
Description: Phase IIa - Udenafil Dose 1, Dose 2(Single dose)~Phase IIb - Udenafil(BID)
Study NCT01553721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Phase IIa - placebo Phase IIb - placebo
Study NCT01877031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A magnetically tracked needle with an associated virtual image will be superimposed on the ultrasound image to give the user a better idea of the position of the needle.
Study NCT01877031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Standard of Care - Ultrasound guided intervention
Study NCT01000519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training
Description: 18 sessions over 2 months period. Each session consist of 50 minutes of aerobic training at 65-70 % of maximum predicted heart rate
Study NCT01000519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Description: 18 sessions completed in 2 months. each session consists of 50 minutes of resistance training which is made up of 3 sets of 10 repetitions of nine resistive exercises using machines and free weights at 65-70% of 1-repetitive maximum.
Study NCT03431142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)
Study NCT03431142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel+aspirin
Description: Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)
Study NCT02778373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitargo ®, Swecarb AB, Karlskrona, Sweden
Study NCT02778373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA
Study NCT02778373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Water
Study NCT02996500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Investigational
Study NCT02996500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02996500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Investigational
Study NCT04459104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic load
Description: Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
Study NCT04694846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive counseling
Study NCT04694846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04459104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low glycemic load
Description: Participants will be given test beverages containing 50gr of isomaltulose (low glycemic index = 32). Isomaltulose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
Study NCT05417035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebido
Description: To evaluate if traditional treatment induces puberty similary to newer treatment
Study NCT05417035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebido
Description: To evaluate if traditional treatment induces puberty similary to newer treatment
Study NCT02654860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 3%
Description: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
Study NCT02654860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection containing Saline solution 0.9%
Description: Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
Study NCT02654860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric Bupivacaine HCl 0.5%
Description: NIMP, spinal anaesthetic before the surgical procedure
Study NCT04459104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High glycemic load
Description: Participants will be given test beverages containing 50gr sucrose (high glycemic index = 65). Sucrose powder will be dissolved in 250mL water, and participants will be instructed to consume this beverage within 5 minutes. Blood glucose levels will be collected at 15, 30, 45, 60, 90, and 120 minutes after consumption of the beverages. The first two drops of blood will be discarded, the third drop will be used for testing.
Study NCT02654860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric Bupivacaine HCl 0.5%
Description: NIMP, spinal anaesthetic before the surgical procedure
Study NCT01235832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avocado Diet
Description: The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (\~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
Study NCT01235832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower-Fat Diet
Description: The Lower-Fat diet will provide \~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
Study NCT01235832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Fat Diet
Description: This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
Study NCT02767882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.
Study NCT02767882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.